Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic value of circulating endothelial cells in glioblastoma patients: a pilot study.
Vaz Salgado MA, Earl J, Berrocal VR, Arrieta FS, Gomez A, Sepulveda-Sanchez JM, Perez-Nuñez Á, de la Fuente EC, Lourido D, Villamayor M, Pian H, Muriel A, Rossi E, Zamarchi R, Carrato A, Ley L. Vaz Salgado MA, et al. Among authors: sepulveda sanchez jm. Future Sci OA. 2022 May 24;8(5):FSO796. doi: 10.2144/fsoa-2022-0008. eCollection 2022 Mar. Future Sci OA. 2022. PMID: 35662744 Free PMC article.
Ocoxin Modulates Cancer Stem Cells and M2 Macrophage Polarization in Glioblastoma.
Hernández-SanMiguel E, Gargini R, Cejalvo T, Segura-Collar B, Núñez-Hervada P, Hortigüela R, Sepúlveda-Sánchez JM, Hernández-Laín A, Pérez-Núñez A, Sanz E, Sánchez-Gómez P. Hernández-SanMiguel E, et al. Oxid Med Cell Longev. 2019 Aug 5;2019:9719730. doi: 10.1155/2019/9719730. eCollection 2019. Oxid Med Cell Longev. 2019. PMID: 31467641 Free PMC article.
Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO).
Sepúlveda-Sánchez JM, Gil-Gil M, Alonso-García M, Vaz Salgado MÁ, Vicente E, Mesía Barroso C, Rodríguez Sánchez Á, Durán G, De Las Peñas R, Muñoz-Langa J, Velasco G, Hernández-Laín A, Hilario A, Navarro Martín M, Benavides M, Oleaga L, Cantero Montenegro D, Ruano Y, Sánchez-Gómez P, Martín-Soberón MC, Morales-Llombart R, Pachón V, Pineda E. Sepúlveda-Sánchez JM, et al. Target Oncol. 2020 Oct;15(5):613-622. doi: 10.1007/s11523-020-00754-6. Target Oncol. 2020. PMID: 33025213 Clinical Trial.
The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas.
Gargini R, Segura-Collar B, Herránz B, García-Escudero V, Romero-Bravo A, Núñez FJ, García-Pérez D, Gutiérrez-Guamán J, Ayuso-Sacido A, Seoane J, Pérez-Núñez A, Sepúlveda-Sánchez JM, Hernández-Laín A, Castro MG, García-Escudero R, Ávila J, Sánchez-Gómez P. Gargini R, et al. Sci Transl Med. 2020 Jan 22;12(527):eaax1501. doi: 10.1126/scitranslmed.aax1501. Sci Transl Med. 2020. PMID: 31969485 Free PMC article.
Immune Profiling of Gliomas Reveals a Connection with IDH1/2 Mutations, Tau Function and the Vascular Phenotype.
Cejalvo T, Gargini R, Segura-Collar B, Mata-Martínez P, Herranz B, Cantero D, Ruano Y, García-Pérez D, Pérez-Núñez Á, Ramos A, Hernández-Laín A, Martín-Soberón MC, Sánchez-Gómez P, Sepúlveda-Sánchez JM. Cejalvo T, et al. Cancers (Basel). 2020 Nov 2;12(11):3230. doi: 10.3390/cancers12113230. Cancers (Basel). 2020. PMID: 33147752 Free PMC article.
Tumor-Derived Pericytes Driven by EGFR Mutations Govern the Vascular and Immune Microenvironment of Gliomas.
Segura-Collar B, Garranzo-Asensio M, Herranz B, Hernández-SanMiguel E, Cejalvo T, Casas BS, Matheu A, Pérez-Núñez Á, Sepúlveda-Sánchez JM, Hernández-Laín A, Palma V, Gargini R, Sánchez-Gómez P. Segura-Collar B, et al. Cancer Res. 2021 Apr 15;81(8):2142-2156. doi: 10.1158/0008-5472.CAN-20-3558. Epub 2021 Feb 16. Cancer Res. 2021. PMID: 33593822 Free article.
Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
Sepúlveda-Sánchez JM, Vaz MÁ, Balañá C, Gil-Gil M, Reynés G, Gallego Ó, Martínez-García M, Vicente E, Quindós M, Luque R, Ramos A, Ruano Y, Pérez-Segura P, Benavides M, Sánchez-Gómez P, Hernández-Laín A. Sepúlveda-Sánchez JM, et al. Neuro Oncol. 2017 Oct 19;19(11):1522-1531. doi: 10.1093/neuonc/nox105. Neuro Oncol. 2017. PMID: 28575464 Free PMC article. Clinical Trial.
Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate.
Sepulveda-Sanchez J, Ramos A, Hilario A, DE Velasco G, Castellano D, Garcia DE LA Torre M, Rodon J, Lahn MF. Sepulveda-Sanchez J, et al. Oncol Lett. 2015 Jun;9(6):2442-2448. doi: 10.3892/ol.2015.3106. Epub 2015 Apr 8. Oncol Lett. 2015. PMID: 26137087 Free PMC article.
IDP-410: a Novel Therapeutic Peptide that Alters N-MYC Stability and Reduces Angiogenesis and Tumor Progression in Glioblastomas.
Gargini R, Segura-Collar B, Garranzo-Asensio M, Hortigüela R, Iglesias-Hernández P, Lobato-Alonso D, Moreno-Raja M, Esteban-Martin S, Sepúlveda-Sánchez JM, Nevola L, Sánchez-Gómez P. Gargini R, et al. Among authors: sepulveda sanchez jm. Neurotherapeutics. 2022 Jan;19(1):408-420. doi: 10.1007/s13311-021-01176-6. Epub 2022 Jan 31. Neurotherapeutics. 2022. PMID: 35099769 Free PMC article.
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.
Lassman AB, Sepúlveda-Sánchez JM, Cloughesy TF, Gil-Gil MJ, Puduvalli VK, Raizer JJ, De Vos FYF, Wen PY, Butowski NA, Clement PMJ, Groves MD, Belda-Iniesta C, Giglio P, Soifer HS, Rowsey S, Xu C, Avogadri F, Wei G, Moran S, Roth P. Lassman AB, et al. Among authors: sepulveda sanchez jm. Clin Cancer Res. 2022 Jun 1;28(11):2270-2277. doi: 10.1158/1078-0432.CCR-21-2664. Clin Cancer Res. 2022. PMID: 35344029 Free PMC article. Clinical Trial.
49 results